Eculizumab for the treatment of an atypical hemolytic uremic syndrome with mutations in complement factor I and C3 Emanuel Ferreira, Nuno Oliveira, Maria Marques, Luís Francisco, Ana Santos, Armando Carreira, Mário Campos

Hepatotoxicity associated with eculizumab in a patient with atypical hemolytic uremic syndrome Aysegul Oruc, Yavuz Ayar, Berna Aytac Vuruskan, Abdulmecit Yildiz, Nimet Aktas, Mahmut Yavuz, Mustafa Gullulu, Kamil Dilek, Alparslan Ersoy

Late onset of de novo atypical hemolytic–uremic syndrome presented on a simultaneous pancreas and kidney transplant recipient successfully treated with eculizumab Francisco Javier Juega-Mariño, Neus Sala, Dolores López, Laura Cañas, Josep Bonet, Ricardo Lauzurica